S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

Immutep Stock Forecast, Price & News

+0.01 (+0.30 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $3.32
50-Day Range
MA: $3.08
52-Week Range
Now: $3.32
Volume372,741 shs
Average Volume850,782 shs
Market Capitalization$129.48 million
P/E RatioN/A
Dividend YieldN/A
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Â'eftilagimod alpha' or Â'efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Immutep logo


Overall MarketRank

1.28 out of 5 stars

Medical Sector

718th out of 1,926 stocks

Pharmaceutical Preparations Industry

364th out of 773 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMMP



Sales & Book Value

Annual Sales$4.92 million
Book Value$0.57 per share



Market Cap$129.48 million
Next Earnings DateN/A
OptionableNot Optionable
+0.01 (+0.30 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMMP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Immutep (NASDAQ:IMMP) Frequently Asked Questions

How has Immutep's stock price been impacted by COVID-19 (Coronavirus)?

Immutep's stock was trading at $2.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMMP stock has increased by 55.9% and is now trading at $3.32.
View which stocks have been most impacted by COVID-19

Is Immutep a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Immutep stock.
View analyst ratings for Immutep
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Immutep?

Wall Street analysts have given Immutep a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immutep wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Immutep's CEO?

1,448 employees have rated Immutep CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Immutep's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What price target have analysts set for IMMP?

2 brokerages have issued 12 month target prices for Immutep's stock. Their forecasts range from $8.00 to $8.00. On average, they expect Immutep's stock price to reach $8.00 in the next year. This suggests a possible upside of 141.0% from the stock's current price.
View analysts' price targets for Immutep
or view Wall Street analyst' top-rated stocks.

Are investors shorting Immutep?

Immutep saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 996,400 shares, an increase of 301.5% from the December 15th total of 248,200 shares. Based on an average daily volume of 5,570,000 shares, the short-interest ratio is currently 0.2 days.
View Immutep's Short Interest

Who are some of Immutep's key competitors?

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include CHF Solutions (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

Who are Immutep's key executives?

Immutep's management team includes the following people:
  • Mr. Marc Voigt, CEO, CFO, Chief Bus. Officer & Exec. Director (Age 47)
  • Ms. Deanne Miller, COO, Gen. Counsel & Company Sec. (Age 43)
  • Dr. Frederic Triebel, Chief Scientific Officer & Chief Medical Officer (Age 65)
  • Mr. Thomas Robert John Bloomfield, Company Sec.
  • Mr. Christian Mueller, Director of Clinical Devel. & Regulatory Affairs
  • Mr. Shengfei Fang, Fin. Director & Assistant Company Sec.

What is Immutep's stock symbol?

Immutep trades on the NASDAQ under the ticker symbol "IMMP."

How do I buy shares of Immutep?

Shares of IMMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immutep's stock price today?

One share of IMMP stock can currently be purchased for approximately $3.32.

How big of a company is Immutep?

Immutep has a market capitalization of $129.48 million and generates $4.92 million in revenue each year.

What is Immutep's official website?

The official website for Immutep is www.immutep.com.

How can I contact Immutep?

Immutep's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company can be reached via phone at 61-2-8315-7003 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.